Shire is a biotechnology company that researches, develops, licenses, manufactures, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The Company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Shire markets its products through wholesalers, distributors, and various pharmacies.
Type
Public
HQ
Dublin, IE
Founded
1986
Size (employees)
23,044 (est)-3%
Website
shire.com
Shire was founded in 1986 and is headquartered in Dublin, IE
Report incorrect company information

Key People/Management at Shire

Flemming Ornskov MD, MPH

Flemming Ornskov MD, MPH

CEO
Thomas Dittrich

Thomas Dittrich

CFO
Andreas Busch

Andreas Busch

Head of Research and Development and Chief Scientific Officer
Bill Mordan

Bill Mordan

General Counsel and Company Secretary
Joanne Cordeiro

Joanne Cordeiro

Chief Human Resources Officer
Perry Sternberg

Perry Sternberg

Head of US Commercial
Show more

Shire Office Locations

Shire has offices in Hanoi, Guaynabo, Cambridge, Bannockburn and in 48 other locations
Dublin, IE (HQ)
50 Baggot Street Lower
Sydney, AU
225 George St
Wien, AT
67 Industriestraße
Bruxelles, BE
47 Rue Montoyer
Chácara Santo Antonio (Zona Sul), BR
Av. das Nações Unidas, 14.171
Sofia, BG
2 2a ul. "Saborna"
Show all (53)
Report incorrect company information

Shire Financials and Metrics

Shire Financials

Shire's revenue was reported to be $15.16 b in FY, 2017 which is a 39.3% increase from the previous period.
USD

Market capitalization (14-Jun-2018)

49.6 b

Closing share price (14-Jun-2018)

162.8
Shire's current market capitalization is $49.6 b.
Annual
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

98.3 m114 m111.4 m103.4 m109.3 m120.6 m122.3 m67.1 m58.2 m47.6 m15.2 b

Revenue growth, %

(9%)16%(2%)(7%)6%10%1%(45%)9467%70%39%

Cost of goods sold

4.7 b

Gross profit

10.5 b
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.5 b1.6 b1.7 b1.7 b2.4 b3.5 b3.6 b3.7 b3.5 b

Cost of goods sold

227.8 m228 m262.7 m248.6 m778.1 m1.7 b1.3 b1.1 b1 b

Gross profit

1.3 b1.3 b1.4 b1.5 b1.7 b1.7 b2.2 b2.6 b2.5 b

Gross profit Margin, %

85%85%84%85%68%50%63%70%72%
Annual
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

135.5 m528.8 m472.4 m

Accounts Receivable

1.2 b2.6 b3 b

Prepaid Expenses

197.4 m806.3 m795.3 m

Inventories

455.3 m544.8 m635.4 m3.6 b3.3 b
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

74.3 m64 m44.9 m69 m693.4 m728.6 m369 m263.7 m209.3 m

Accounts Receivable

1.1 b1.1 b1.3 b1.3 b2.4 b2.6 b2.6 b2.8 b2.8 b

Prepaid Expenses

216.6 m221.6 m215 m314.4 m733.6 m665.3 m787.2 m778.5 m779.9 m

Inventories

588.7 m632.8 m608.9 m680 m5.8 b4.9 b3.3 b3.3 b3.4 b
Annual
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

7.5 m15.1 m4.7 m(1.9 m)(2.7 m)1.6 m1.6 m(2.9 m)2.9 m2.5 m4.3 b

Depreciation and Amortization

324.4 m407.3 m637.2 m1.5 b2.3 b

Inventories

(63.2 m)(255.8 m)(145.1 m)

Accounts Payable

109.2 m621.6 m(526.8 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

410.4 m570 m1 b419 m256.9 m(129.9 m)375 m615.3 m1.2 b

Depreciation and Amortization

120.6 m291.8 m457.4 m168.9 m429.8 m877.8 m486.9 m1 b1.6 b

Inventories

(22 m)(37.4 m)(21.7 m)(32.2 m)(116.4 m)(228 m)(151.8 m)(171.6 m)(245.2 m)

Accounts Payable

77.5 m(39.8 m)56.5 m(154.6 m)342.7 m315.2 m(671.5 m)(445.1 m)(557.8 m)
Show all financial metrics

Shire Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Phase I Trials Products

7 6 6 7

Phase II Trials Products

11 6 10 10

Phase III Trials Products

7 14 17 15

Phase Approved

2 3 4 7
Show all operating metrics

Shire Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Baxalta January 11, 2016$32 b
Dyax November 02, 2015$5.90 b
Foresight Biotherapeutics August 03, 2015$300 m
Meritage Pharma February 24, 2015$245 m
NPS Pharmaceuticals, Inc. January 11, 2015$5.20 b
Lumena Pharmaceuticals May 13, 2014$260 m
Fibrotech Therapeutics May 02, 2014$75 m
ViroPharma Incorporated November 11, 2013$4.20 b
SARcode Bioscience March 25, 2013$160 m
Premacure March 12, 2013
Show more

Shire Revenue Breakdown

Embed Graph

Shire revenue breakdown by business segment: 11.6% from Internal Medicine, 30.2% from Immunology, 18.4% from Neuroscience, 10.0% from Genetic Diseases, 26.2% from Hematology and 3.6% from Other

Report incorrect company information

Shire Online and Social Media Presence

Embed Graph
Report incorrect company information

Shire News and Updates

FiercePharmaAsia—Sun’s key Halol plant, Eisai’s new Alzheimer’s center, Takeda-Shire opponents

Sun Pharma finally frees its key plant for the U.S. market from FDA restrictions; Eisai will open up a new genetics-driven drug discovery site focused on Alzheimer's disease; opponents to Takeda's $62 billion deal for Shire look to rally enough support to call off the transaction; and more.

Bay Area Startup Wins Prestigious Boston Healthcare Competition

SAN FRANCISCO, June 12, 2018 /PRNewswire/ -- InsightRX, a precision medicine company, won the Platinum Award at the prestigious PULSE@MassChallenge program last Tuesday night.  A panel of judges drawn from hospital systems, healthcare companies, and insurers across greater Boston awarded I...

Takeda shareholder group aims to block $62bn Shire deal

A group of Takeda shareholders is working to block the $62bn (£46.4bn) acquisition of Shire, news agency Reuters reported today. Japanese drug company Takeda is holding a shareholder meeting later this year to approve an issue of new stock to help fund the deal for London-listed Shire. Read mo…

Takeda shareholder group aims to block $62 billion Shire deal

TOKYO (Reuters) - A group of Takeda Pharmaceutical Co Ltd shareholders is trying to build support to block the $62 billion acquisition of London-listed Shire Plc at an extraordinary general meeting, a leading member of the group told Reuters on Monday.
Show more
Report incorrect company information